title: Bortezomib and dexamethasone as first-line therapy for a patient with newly diagnosed polyneuropathy, organomegaly, endocrinopathy, M protein and skin changes syndrome complicated by renal failure.
authors.forename: Jian
authors.initials: J
authors.lastname: Li
authors.forename: Wei
authors.initials: W
authors.lastname: Zhang
authors.forename: Wen-Ying
authors.initials: WY
authors.lastname: Kang
authors.forename: Xin-Xin
authors.initials: XX
authors.lastname: Cao
authors.forename: Ming-Hui
authors.initials: MH
authors.lastname: Duan
authors.forename: Dao-Bin
authors.initials: DB
authors.lastname: Zhou
mesh_terms: D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D003907:Dexamethasone / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006801:Humans; D060828:Induction Chemotherapy / Q000379:methods; D008297:Male; D008875:Middle Aged; D016878:POEMS Syndrome / Q000150:complications / Q000188:drug therapy*; D011719:Pyrazines / Q000627:therapeutic use*; D051437:Renal Insufficiency / Q000150:complications / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D000970:Antineoplastic Agents; D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib; D003907:Dexamethasone